Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    College Station, TX

    Search
    College Station, TX
    Show Map
    Map View
    College Station, TX
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      217 Clinical Trials near College Station, TX

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Risankizumab for Psoriatic Arthritis

      Tomball, Texas
      The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Hypersensitivity To Risankizumab, Others

      444 Participants Needed

      Upadacitinib for Rheumatoid Arthritis

      Tomball, Texas
      The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Adalimumab, Inadequate BDMARD Response, Others
      Must Be Taking:Methotrexate

      1629 Participants Needed

      Baxdrostat + Dapagliflozin for Heart Failure

      Tomball, Texas
      Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD. In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Severe Hepatic Impairment, Others
      Must Be Taking:SGLT2 Inhibitors

      11300 Participants Needed

      Orforglipron for Pediatric Obesity

      Tomball, Texas
      The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Weight Reduction Surgery, Type 1 Diabetes, Thyroid Carcinoma, Others

      125 Participants Needed

      mRNA-1403 for Stomach Flu

      Tomball, Texas
      The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Chronic GI Disease, Immunodeficiency, Others
      Must Not Be Taking:Immunosuppressants, Blood Products

      28000 Participants Needed

      Ziltivekimab for Heart Failure and Inflammation

      Tomball, Texas
      The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Stroke, Hypertension, Others

      680 Participants Needed

      Upadacitinib for Lupus

      The Woodlands, Texas
      Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 63

      Key Eligibility Criteria

      Disqualifiers:Lupus Nephritis, Neuropsychiatric SLE, Overlap Syndromes, Others
      Must Be Taking:Antimalarials, Corticosteroids, Immunosuppressants

      1000 Participants Needed

      Litifilimab for Lupus

      The Woodlands, Texas
      This trial is testing litifilimab, a medication for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can safely reduce the immune system's attack on the body, helping to manage symptoms and prevent organ damage. Litifilimab has shown promise in reducing the number of swollen and tender joints in SLE patients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Early Terminators, Organ-specific Lupus, Others
      Must Be Taking:Antimalarials, Steroids, Immunosuppressants

      864 Participants Needed

      Upadacitinib for Psoriatic Arthritis

      Tomball, Texas
      A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Tuberculosis, Hepatitis, HIV, Others
      Must Not Be Taking:JAK-inhibitors, TYK2-inhibitors

      100 Participants Needed

      COVID-19 Vaccines for Rheumatic Diseases

      Woodland, Texas
      Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:HIV/AIDS, Active SARS-CoV-2, Others
      Must Be Taking:TNF Antagonists, B-cell Depletion

      129 Participants Needed

      Tirzepatide for Psoriatic Arthritis

      Tomball, Texas
      The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Thyroid Cancer, Others
      Must Be Taking:Ixekizumab

      200 Participants Needed

      Dupilumab for Asthma

      Tomball, Texas
      This trial is testing dupilumab, a medication that reduces lung inflammation, in adults with moderate to severe asthma that isn't controlled by usual treatments. It aims to see if dupilumab can help improve breathing and slow down lung damage.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:COPD, Active Infection, Cancer, Others
      Must Be Taking:Inhaled Corticosteroids, LABA

      1324 Participants Needed

      Rosnilimab for Rheumatoid Arthritis

      Tomball, Texas
      This trial is testing Rosnilimab, a new medication, to see if it can help people with moderate to severe rheumatoid arthritis by reducing joint pain and swelling. The study will check if the medication is safe and effective.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Inflammatory Joint Disease, Cancer, Others
      Must Be Taking:CsDMARDs

      420 Participants Needed

      SPY072 for Rheumatoid Arthritis

      Tomball, Texas
      This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Autoimmune, Rheumatologic, Others
      Must Not Be Taking:Multiple BDMARDs, TsDMARDs

      285 Participants Needed

      PF-07328948 for Heart Failure

      Tomball, Texas
      The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Liver Cirrhosis, Others
      Must Not Be Taking:SGLT2 Inhibitors

      620 Participants Needed

      AlloNK + Rituximab for Rheumatic Diseases

      Woodland, Texas
      A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Bipolar, Others
      Must Be Taking:Biologic DMARDs

      90 Participants Needed

      Targeted Therapies for Rheumatoid Arthritis

      Tomball, Texas
      Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Juvenile Arthritis, Other Joint Diseases
      Must Be Taking:Methotrexate

      180 Participants Needed

      Verekitug for Asthma

      Tomball, Texas
      The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Conditions, Pregnancy, Protocol Deviations, Others

      436 Participants Needed

      Risankizumab + Lutikizumab for Psoriatic Arthritis

      Tomball, Texas
      Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutikizumab. Participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. Around 120 participants will be enrolled in the study at approximately 40 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:HIV, Active HBV, Active HCV, Others

      120 Participants Needed

      LY3541860 for Rheumatoid Arthritis

      Tomball, Texas
      The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Malignant Disease, Chronic Kidney Disease, Others
      Must Not Be Taking:Corticosteroids, Opioids, JAK Inhibitors

      40 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Trial

      Flu and COVID-19 Vaccines for Coronavirus and Influenza

      Tomball, Texas
      The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Flu Or COVID Vaccine
      Must Not Be Taking:Antivirals

      2645 Participants Needed

      Obeldesivir for RSV

      Tomball, Texas
      The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection. It will also look at how well ODV helps reduce the time it takes for children to feel better and for their RSV symptoms to improve. The primary objectives of this study are: a) to evaluate the safety and tolerability of ODV in pediatric participants with RSV infection; b) To evaluate the efficacy of ODV on time to alleviation of targeted RSV symptoms in pediatric participants with RSV infection.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:< 5

      Key Eligibility Criteria

      Disqualifiers:Asthma, Cystic Fibrosis, Immunocompromised, Others
      Must Not Be Taking:Antivirals, Antibacterials

      130 Participants Needed

      IMVT-1402 for Rheumatoid Arthritis

      Tomball, Texas
      This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA). The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Immunodeficiency, Others
      Must Not Be Taking:Rituximab, Anti-FcRn

      120 Participants Needed

      Flu and COVID-19 Vaccines for Virus Protection

      Tomball, Texas
      This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Flu Or COVID Vaccine
      Must Not Be Taking:Antivirals

      1353 Participants Needed

      Oral Vaccine for COVID-19

      Tomball, Texas
      The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune, Immunodeficiency, Cancer, Others
      Must Not Be Taking:Antibiotics, Antacids, NSAIDs, Others

      10400 Participants Needed

      Maridebart Cafraglutide for Diabetes

      Tomball, Texas
      The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Cardiovascular Events, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      409 Participants Needed

      Amlitelimab for Celiac Disease

      Tomball, Texas
      This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied. Study details include: The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension. The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension. The double-blind placebo-controlled treatment duration will be up to 28 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Refractory Celiac, Inflammatory GI, Autoimmune, Others
      Must Not Be Taking:NSAIDs, Immunosuppressants, Corticosteroids, Others

      204 Participants Needed

      Pneumococcal Vaccine for Children

      Tomball, Texas
      The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during some clinic visits.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:12 - 15

      Key Eligibility Criteria

      Disqualifiers:Severe Allergic Reaction, Congenital Malformation, Others

      225 Participants Needed

      mRNA Vaccine for COVID-19 and Flu

      Tomball, Texas
      The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 64

      Key Eligibility Criteria

      Disqualifiers:Chronic Conditions, Immunodeficiency, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants, Others

      932 Participants Needed

      JK07 for Heart Failure

      Tomball, Texas
      This trial is testing a new medication called JK07 in people aged 18-85 who have heart failure. The study includes two groups based on how well their heart is pumping. Participants will receive either a low dose or high dose of JK07. The goal is to see if JK07 can improve heart function and help these patients feel better.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Stroke, Syncope, Others
      Must Be Taking:Anticoagulants

      282 Participants Needed

      1...678

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in College Station, TX pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in College Station, TX work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in College Station, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in College Station, TX is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in College Station, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in College Station, TX?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in College Station, TX?

      Most recently, we added Enlicitide + Rosuvastatin for High Cholesterol, Beef vs Plant Protein for Protein Metabolism and CD388 for Flu Prevention to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Texas

      Anxiety Clinical Trials in Texas

      Schizophrenia Clinical Trials in Texas

      ADHD Clinical Trials in Texas

      Bipolar Disorder Clinical Trials in Texas

      Multiple Sclerosis Clinical Trials in Texas

      Autism Clinical Trials in Texas

      Treatment Resistant Depression Clinical Trials in Texas

      Borderline Personality Disorder Clinical Trials in Texas

      Social Anxiety Disorder Clinical Trials in Texas

      Parkinson's Disease Clinical Trials in Texas

      Alzheimer's Disease Clinical Trials in Texas

      By Location

      Clinical Trials near Houston, TX

      Clinical Trials near Dallas, TX

      Clinical Trials near San Antonio, TX

      Clinical Trials near Austin, TX

      Clinical Trials near Fort Worth, TX

      Clinical Trials near Plano, TX

      Clinical Trials near Tyler, TX

      Clinical Trials near El Paso, TX

      Clinical Trials near Lubbock, TX

      Clinical Trials near Galveston, TX

      Clinical Trials near Temple, TX

      Clinical Trials near Arlington, TX

      Other People Viewed

      By Subject

      Top Clinical Trials near College Park, MD

      Top Clinical Trials near College Park, GA

      218 Clinical Trials near Bryan, TX

      190 Clinical Trials near Grapevine, TX

      214 Clinical Trials near Arlington, TX

      41 Psoriasis Trials near San Antonio, TX

      Top Clinical Trials near Duncanville, TX

      Top Clinical Trials near Denton, TX

      Top Clinical Trials near Denison, TX

      Top Clinical Trials near Brownsville, TX

      Top Clinical Trials near Beaumont, TX

      Top Clinical Trials near Amarillo, TX

      By Trial

      Hookworm Vaccine for Hookworm Infection

      Magnesium L-Threonate for Athletic Performance

      Virtual Community Intervention for Social Connectedness

      Decision Support Tool for Prediabetes

      Outdoor Walks for Depression

      Personalized Integrated Prevention Program for Reducing Heavy Drinking and Sexual Assault on College Campuses

      Virtual Reality Therapy for Anxiety

      Voice-Activated Smart Speakers for Mild Cognitive Impairment

      Tafasitamab + Lenalidomide + Rituximab for Follicular & Marginal Zone Lymphoma

      e-PBI+ for College Substance Abuse

      Concizumab for Hemophilia

      ALN-SOD for ALS

      Related Searches

      Chemotherapy + Immunotherapy for Recurrent Ovarian Cancer

      BGB-11417 + Dexamethasone + Carfilzomib for Multiple Myeloma

      Exparel for Postoperative Pain

      Tai Ji Quan for Mild Cognitive Impairment

      Voice-Activated Technology for Frailty

      Treatment Intensity for Acute Myeloid Leukemia

      Combination Therapy for Non-Small Cell Lung Cancer

      Olaparib for Pediatric Cancer

      Lifestyle Intervention for Obesity

      Top Clinical Trials near Adairsville, GA

      Time-Restricted Eating for Cancer Side Effect Reduction

      N-acetylcysteine for Retinitis Pigmentosa